Nonclinical factors are more likely to drive discontinuation of biologic therapy for patients with severe asthma.

Real-world data from 2016 to 2025 highlight the changing landscape of biologic use and the growing preference for tezepelumab in asthma.

Biologic therapy during pregnancy was not associated with adverse outcomes for most patients in a retrospective study presented at AAAAI 2026.

Please provide your email address to receive an email when new articles are posted on . Biologic therapies are underutilized in non-white populations. By identifying barriers to specific biologic ...

Experts in dermatology presented ways in which biologic therapies can be given and the duration of treatment when used in pediatric patients with skin conditions. Treating pediatric patients with ...

Please provide your email address to receive an email when new articles are posted on . Less than 15% of PCPs reported managing patients with uncontrolled asthma at least once a week. More PCPs ...

Starting biologic therapy at diagnosis, rather than escalating later, may significantly reduce complications and ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

Key highlights include a strong emphasis on dupilumab, particularly in steroid-dependent asthma and in patients showing inadequate response to initial biologic therapy. The recommendations stress the ...

Antibiotic exposure in psoriasis patients is linked to increased biologic therapy discontinuation, with risk rising with multiple courses, suggesting gut microbiota alterations may play a role. The ...

Chicago, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The global asthma drugs market size was valued at USD 26.52 billion in 2025 and is projected to hit the market valuation of USD 41.18 billion by 2035 at a ...